News | Stents Drug Eluting | September 01, 2017

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

Landmark data published by The Lancet demonstrates statistically significant lower event rates with Orsiro

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the European Society of Cardiology’s ESC Congress 2017, August 26-30 in Barcelona, Spain, and published by The Lancet show 6.2 percent versus 9.6 percent 12-month TLF rate, demonstrating statistically significant improved clinical outcomes with Orsiro in percutaneous coronary intervention (PCI).

This pivotal U.S. investigational device exemption (IDE) trial included a large, complex patient population and was designed in collaboration with the U.S. Food and Drug Administration (FDA) to support an upcoming premarket approval submission.

Highlights of the BIOFLOW-V study include the following 12-month data points comparing Orsiro to Xience:

  • 6.2 percent versus 9.6 percent TLF rate (p=0.04);
  • 4.7 percent versus 8.3 percent target vessel myocardial infarction (MI) rate (p=0.02);
  • 2 percent versus 2.4 percent clinically driven target lesion revascularization (cd-TLR) rate; and
  • 0.5 percent versus 0.7 percent Academic Research Consortium (ARC) definite/probable stent thrombosis rate.

In a pooled analysis with prior Orsiro randomized control trials versus Xience, BIOFLOW-II and BIOFLOW-IV, Orsiro demonstrated statistically significant improved outcomes and clear non-inferiority. Mean estimates of TLF at 12 months are 6.3 percent with Orsiro versus 8.9 percent with Xience, resulting in a mean difference of -2.6 percent, demonstrating a 100 percent probability of Orsiro being non-inferior to the control. A post-hoc superiority analysis showed a 96.9 percent probability of Orsiro being superior to the control.

“Orsiro’s rate of TLF shows an unprecedented improvement in DES outcomes compared with a control stent that has served as a standard in interventional cardiology,” said U.S. principal investigator David Kandzari, M.D., Piedmont Heart Institute, Atlanta. “Orsiro also notably has exceptional deliverability that is essential for PCI procedures. We believe Orsiro’s ultrathin 60 micron struts, bioresorbable polymer and proven antiproliferative drug are the key elements to its superior performance.”

BIOFLOW-V is the first large randomized trial to show improved outcomes of any DES over Xience. The international study included 1,334 patients (884 Orsiro: 450 Xience) and showed that Orsiro outcomes were statistically better for TLF and target vessel MI rates than Xience in a sizable, complex population. Fifty-point-eight (50.8) percent of patients presented with an acute coronary syndrome, 35 percent of patients were diabetic and 73.8 percent of lesions were ACC/AHA Class B2/C. Patients will be followed for five years.

The BIOFLOW-V study design was published by the American Heart Journal.

For more information: www.thelancet.com

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init